inTEST Corporation (INTT) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance, with record high revenue, improved gross margins, and debt reduction. The Q&A highlights cautious optimism, with growth expected in automotive and life sciences. Despite modest semi recovery guidance, the company is well-positioned for future growth, supported by new product launches and market diversification. While management's conservative guidance may temper expectations, the overall sentiment is positive, suggesting a likely stock price increase of 2% to 8%.
Key Financial Performance
Revenue $32.8 million in Q4 2025, a 25% increase from $26.2 million in Q3 2025, but a $3.8 million decline compared to Q4 2024. The increase from Q3 was due to improved capital spending and new product sales, while the year-over-year decline was attributed to lower auto EV, semi, and safety security revenue.
Backlog $53.9 million at year-end 2025, representing a 36% increase over year-end 2024 and a 9% sequential increase. This growth was driven by market diversification and increased customer adoption in non-semi markets.
Gross Margin 45.4% in Q4 2025, up from 41.9% in Q3 2025 and a 570 basis point increase year-over-year. The improvement was due to higher sales of new Alfamation products, cost reduction initiatives, and a favorable product mix.
Operating Expenses $13.6 million in Q4 2025, an increase of $1.4 million sequentially and $1.2 million year-over-year. The sequential increase was due to higher sales commissions and marketing activities, while the year-over-year increase included nonrecurring amortization credits and restructuring charges.
Adjusted EBITDA $3.2 million in Q4 2025, representing a 9.7% margin, up from $400,000 (1.5% margin) in Q3 2025. The improvement reflects operational leverage as revenue recovered.
Net Income $1.2 million in Q4 2025, translating to $0.10 per diluted share. Adjusted EPS was $0.16 per diluted share, adding back tax-affected amortization and restructuring charges.
Debt Reduction $1.4 million reduction in Q4 2025 and $7.6 million reduction for the full year 2025, leaving total debt at $7.5 million. This was achieved while maintaining substantial liquidity.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New product adoption: Growing market acceptance of new products, particularly from Alfamation and Acculogic, contributed meaningfully to revenue and gross margin. New product revenue is trending towards the Vision 2030 goal of generating 25% of revenue from new product sales.
Market diversification: Revenue diversification into industrial, defense, aerospace, and life sciences markets contributed to 80% of Q4 revenue, reducing dependency on the semi business. Non-semi revenues have grown at a 20% CAGR over the past 5 years.
Geographic expansion: The establishment of a Malaysia manufacturing hub in 2023 and expanded European footprint through the Alfamation acquisition in 2024 enhanced customer reach and relationships in these regions.
Manufacturing efficiency: Cost actions and manufacturing efficiency initiatives throughout 2025 improved gross margins to 45.4% in Q4, despite lower semi contributions.
Operational leverage: Incremental revenue growth was achieved with minimal increase in operating expenses, demonstrating effective cost discipline and scalability.
Vision 2030 strategy: Focus on revenue diversification and new product innovation to reduce dependency on semi cyclicality and achieve sustainable growth.
Structural changes: Operational excellence initiatives and regional expansions are expected to drive long-term profitability and growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Customer hesitation to spend on capital projects: Driven by tariff and macroeconomic uncertainties, as well as ongoing soft demand in the semiconductor business, impacting revenue and growth.
Semiconductor market weakness: Year-over-year orders and revenue in the semiconductor market have declined significantly, reducing the company's ability to spread fixed manufacturing costs and impacting overall profitability.
Slower-than-anticipated capital spending recovery: Non-semiconductor end markets experienced slower recovery in capital spending, contributing to revenue declines.
Geopolitical and tariff uncertainties: Potential changes in tariff policy or broader geopolitical environment could impact operations, though not explicitly factored into 2026 guidance.
Dependence on new product adoption: The company's growth strategy heavily relies on customer adoption of new products, which may pose risks if adoption rates slow or fail to meet expectations.
Operating expense increases: Higher sales commissions, marketing activity, and restructuring charges have increased operating expenses, which could pressure margins if revenue growth does not keep pace.
Cyclicality of semiconductor business: Despite diversification efforts, the semiconductor business remains a significant portion of operations, exposing the company to cyclical downturns.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections for Q1 2026: Revenue is projected to be between $31 million and $33 million.
Revenue Projections for Full Year 2026: Revenue is expected to be between $125 million and $130 million, representing approximately 12% growth over 2025.
Gross Margin Projections: Gross margin for Q1 2026 is expected to be approximately 44%, while for the full year 2026, it is projected to be approximately 45%.
Operating Expenses: Operating expenses for Q1 2026 are projected to be between $13.3 million and $13.7 million. For the full year 2026, operating expenses are expected to be between $53 million and $55 million.
Capital Expenditures: Capital expenditures for 2026 are expected to be 1% to 2% of revenue, consistent with historical investment levels.
Market Trends and Diversification: The company anticipates diversified demand growth in industrial, aerospace, defense, auto EV, and life sciences markets, supported by a growing backlog. No meaningful rebound in semiconductor sales is expected.
New Product Contributions: New higher-margin products are expected to contribute significantly to revenue and gross margin growth in 2026.
Backlog Visibility: Approximately 60% of the backlog is expected to ship beyond Q1 2026, providing forward visibility into the year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you elaborate on the modest growth in the semi space for the back half of 2026?
A:The guidance provided is based on a modest recovery in the semi space, which could be conservative. Historically, semi has come back strong, and the company is well-positioned to capture that growth if it happens. The guidance reflects what the company is confident in achieving.
Q:How is the 2027 automotive program progressing, and what are the expectations for auto orders in 2026?
A:The 2027 automotive program is progressing well, with customers moving forward with investments in Q3 and Q4. Auto demand hasn't taken off yet, but inventories have been worked down. The company is well-positioned to support new model year programs, which are expected to drive demand as they roll out.
Q:What is driving the growth in Life Sciences orders and revenue?
A:Life Sciences growth is driven by a concentrated effort in the MedTech space, including glucometer electronic testing and applications in induction heating and imaging. The company has diversified into MedTech with Alfamation and Acculogic Group, and sees this as a low-penetration area with good growth potential.
Q:How is the company positioned in the back-end test space for semi?
A:The company is well-positioned in the back-end test space, supported by traditional EMS business and thermal solutions for chip and electronics testing. New product launches have broadened the customer base and regained competitive accounts, positioning the company to benefit from growth as investments in testing spaces increase.
Q:What is the outlook for the silicon carbide space, and how is the company positioned?
A:The company is well-positioned in the silicon carbide and gallium nitride space, serving multiple players in crystal growth and epitaxy. Growth is expected to return in the second half of 2026, with a more meaningful impact in 2027. The company is ready to scale up to support customer needs as demand increases.
Q:What are the expectations for gross margins and the impact of semi recovery?
A:Gross margins have improved due to efficiencies and favorable product mix. Semi recovery, particularly in the back-end, could positively impact margins. While reaching 50% margins is unlikely, a strong semi recovery could lead to significant margin improvement.
Q:What is the expected cadence of growth and margin improvement in 2026?
A:The company expects cautious sequential growth throughout 2026, with modest semi upside baked into the guidance. Growth is expected to build over the year, with a potential step-up in margin improvement in the second half as semi contributions increase.
Q:What is the current bookings activity and sector momentum?
A:The company has had two strong quarters of bookings, driven by automotive exposure at Alfamation. While bookings at Alfamation may moderate, the overall funnel is healthy, and the company is well-positioned to deliver on its guidance.
Q:How has the company factored incentive compensation into its guidance?
A:Incentive compensation has been factored into the guidance. If the company performs better than expected, there could be an operating expense impact from increased incentive compensation.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the potential for reaching 50% gross margins, stating it would require a high percentage of back-end semi contribution. Additionally, they did not provide clear data on the exact timing or scale of semi recovery in 2026, using cautious and conservative language instead.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Acculogic line
Aerospace Life
Alfamation product
Auto EV
Defense Aerospace
EV life
Industrial
Life Sciences
Sciences order
Vision
acceptance product
adoption
capital spending
contribution margin
end market
improvement
inTEST
income
inventory step
lift
manufacturing efficiency
momentum order
momentum product
order book
place
product sale
profile
profitability Slide
recovery
restructuring charge
sale margin
semi basis
tax amortization
term loan
trend
INTT Transcript
InTest Corporation (INTT) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call revealed strong financial performance with a 15% revenue increase and improved gross margins. Despite the absence of strategic initiatives and operational updates, the positive financial metrics and increased EPS indicate a healthy business outlook. The lack of negative sentiment in the Q&A further supports a positive stock price movement prediction.
inTEST Corporation (INTT) Q4 2025 Earnings Call Transcript
Positive2-27
The earnings call reveals strong financial performance, with record high revenue, improved gross margins, and debt reduction. The Q&A highlights cautious optimism, with growth expected in automotive and life sciences. Despite modest semi recovery guidance, the company is well-positioned for future growth, supported by new product launches and market diversification. While management's conservative guidance may temper expectations, the overall sentiment is positive, suggesting a likely stock price increase of 2% to 8%.
inTEST Corporation (INTT) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call reveals mixed signals: strong order growth in key sectors and successful diversification efforts are positive, but revenue and gross profit declines, limited market recovery visibility, and flat guidance despite resolved challenges are concerning. The Q&A section highlights management's confidence, yet lacks clarity on guidance adjustments. Market conditions remain weak, especially in the semi sector, and margin declines further temper optimism. Overall, the sentiment remains neutral as positive long-term fundamentals balance short-term uncertainties and financial performance issues.
inTEST Corporation (INTT) Q2 2025 Earnings Call Transcript
Unknown8-6
The earnings call shows mixed signals. Basic financial performance is weak due to net losses, but cost-saving measures and debt reduction are positive. Product development and market strategy are promising with growth in orders and geographic expansion plans. However, uncertainties in the semi business rebound and vague guidance impact sentiment. Shareholder returns are not mentioned, and the Q&A reveals some management evasiveness. Overall, the stock is likely to remain stable, with a neutral sentiment.
INTT Slides
INTT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
